MicroPhage (Longmont) aims to become a worldwide leader in rapid bacterial diagnostics, both identification and antibiotic susceptibility & resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics. The lead Dx products expected in late 2008 are for the identification of methicillin-resitant Staphylococcus aureus (MRSA). Follow-on Dx products for additional bacterial pathogens may include: Vancomycin-resistant [...]